{
  "id": 1921738,
  "title": "Why is Merck stock surging today?",
  "url": "https://urgent.news/2026/08/19/why-is-merck-stock-surging-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-19T11:18:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-merck-stock-surging-today-93CH-4867123"
  },
  "original_language": "en",
  "account": "Merck's stock experienced a significant surge of 6.2% in pre-market trading after the company revealed positive results from Phase 3 INTerpath-001 trial. This trial of intismeran autogene combined with Keytruda met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with stage IIB-IV melanoma. The trial involved 1,137 patients and marked the first large-scale confirmation of the mRNA-based individualized neoantigen therapy platform. This promising result came on the heels of positive actions from analysts such as Daiwa, which upgraded Merck to Outperform, and Wells Fargo, which issued a Buy rating. These upgrades reflected growing confidence in Merck's oncology and HIV pipeline, which is expected to de-risk the company's post-Keytruda patent cliff narrative. The combination of the Phase 3 data and the upgrade cycle amplified the pre-market reaction, while the broader market showed little support, with the S&P 500 and Nasdaq only showing marginal gains or losses. Merck's peers, Pfizer and AbbVie, did not report similar catalysts today, making MRK a sector standout. The success of the Phase 3 INTerpath-001 trial strengthens the commercial case for the intismeran autogene platform across multiple tumor types and opens the door to additional Phase 3 studies in non-small cell lung cancer.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Vaccine stocks jump on Moderna’s melanoma vaccine trial results",
        "url": "https://urgent.news/2026/08/19/vaccine-stocks-jump-on-modernas-melanoma-vaccine-trial-results",
        "published": "2026-08-19T11:21:15.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}